Aardvark Therapeutics, Inc. — Cash Flow Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Capital Allocation Waterfall
Buybacks vs Stock-Based Comp
Cash Flow
Cash Flow by Activity
Operating Cash Flow↓-420.0% -$9M
$-11M
Free Cash Flow↑+100.0% +$6K
$0
Investing Cash Flow
$24M
Financing Cash Flow
$274K
Capex↓-100.0% -$6K
$0
Stock-Based Comp↑+813.9% +$1M
$2M
D&A↑+25.0% +$2K
$10K
SBC Allocated Expense↑+813.9% +$1M
$2M